CaPtivate Pharmaceuticals

Product Development

CaP-adjuvanted Influenza Vaccines (for injection and/or intranasal administration)

Influenza claims the lives of about 100 children in the U.S. every year and hospitalizes around 20,000. About half of children who die because of influenza were previously healthy. Influenza is the 8th-leading cause of death in the United States among people of all ages. Although live attenuated influenza vaccines (e.g. FluMist) have been used for intranasal immunization, attenuated vaccines are not recommended for immune-compromised individuals. We previously reported positive results from mice studies demonstrating that CaP nanoparticle adjuvant is safe and effective for injection or intranasal (mucosal) administration in vaccines against seasonal influenza strains as well as vaccine against H5N1 (avian flu), and pandemic 2009 H1N1 (swine flu). We demonstrated that, CaP-adjuvanted influenza vaccines can induce systemic as well as mucosal antibodies. The availability of pandemic influenza vaccines with enhanced immunogenicity would help spare valuable antigen doses and thus expand the available vaccine supplies. This would substantially improve the ability of nations to rapidly response and protect their people during an influenza pandemic.

We seek partnerships to conduct a dose-response and live-virus challenge studies in ferrets to demonstrate the efficacy of using CaP to develop:

A trivalent flu vaccine (seasonal strains + pandemic H1N1) for intranasal and/or intramuscular administration.